Polidocanol Sclerotherapy of Pharynges for Obstructive Sleep Apnea (OSA) and Snoring Subjects(SS)

Liaoyang Central Hospital30 enrolled

Overview

The aim of this prospective study is to evaluate the results of polidocanol sclerotherapy of pharynx for OSAS \& SS,to reduce pharyngeal compliance.

Polidocanol submucous sclerosis in the part of pharynges with 1% polidocanol injection.The injection should be in the retropharyngeal submucosa and lateral pharyngeal bands and lateral pharyngeal submucosa and in front submucosa of soft palate.The injection is multi-point,and each point injection is 0.3\~0.5ml;the total quantity/each time is not more than 5ml.Every patient have to be treated about 1\~2 time.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Apnea Snoring

Interventions

Polidocanol SclerotherapyDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * OSAS \& SS which palatopharyngeal collapse. Exclusion Criteria: * obstructive sleep apnea syndrome (osas) \& snoring subjects (ss),which anatomic narrow result in.

Outcomes

Primary Outcomes

apnea-hypopnea index (AHI)is on polysomnography(PSG),to compare AHIanterior and posterior treatment.

Secondary Outcomes

Arterial oxygen saturation (SaO2) and body mass index (BMI)will be measured on polysomnography

Central Contacts

Hongyan Chen, MB

CONTACT

+86-0419-3221423 lychy2006@yahoo.com.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.